Search

Search Constraints

You searched for: Author/Creator Lortholary, Alain

Search Results

1. 2022-RA-605-ESGO Long term quality of life after chemotherapy among rare ovarian cancer survivors: the national gineco case-control Vivrovaire Rare Tumors study. (20th October 2022)

2. 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial. Issue 10191 (29th June 2019)

3. 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial. Issue 10191 (29th June 2019)

4. Association and performance of polygenic risk scores for breast cancer among French women presenting or not a familial predisposition to the disease. (January 2023)

5. AXIN2 germline testing in a French cohort validates pathogenic variants as a rare cause of predisposition to colorectal polyposis and cancer. Issue 4 (21st December 2022)

6. Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial. Issue 5 (May 2020)

8. Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study. Issue 5 (May 2016)

9. Cardiac toxicity events in the PHARE trial, an adjuvant trastuzumab randomised phase III study. Issue 13 (September 2015)

10. Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis. (July 2021)